ALAnouk Leathead

Anouk Leathead

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anouk Leathead has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study

    by Anouk Leathead, Nick Lee, Adel Arezki, David Bouhadana, Liam Murad, Tarek Benzouak, Iman Sadri, Rosie Foucault, Aalya Hamouda, Jeffrey Sioufi, et al.

    Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.

  • Open Access

    Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database

    by Joshua D. Cabral, Margaret Gannon, Gregory Raster, David J. Nusbaum, David Bouhadana, Adel Arezki, Aalya Hamouda, Anouk Leathead, Ilan Ohana, Rosie Foucault, et al.

    Objective: The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort. Patients and Methods: We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate ( Q max ) and PVR at regular intervals over 24 months. Results: A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q max and PVR post‐operatively. Conclusion: This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.